Drugs / GSK2604409A
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01204671 Comparator | Oct 2010 → Jun 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01196988 Comparator | Oct 2010 → Jun 2011 | influenza | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2604409A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01204671 ↗ |
| Modality | Vaccine | “The GSK2604409A vaccine” NCT01204671 ↗ |
| Route | Intramuscular | “The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.” NCT01204671 ↗ |